IMP Dehydrogenase Inhibitors as Immunomodulators
dc.contributor.author | Mitchell, Beverly S. | en_US |
dc.contributor.author | Dayton, Jennifer S. | en_US |
dc.contributor.author | Turka, Laurence A. | en_US |
dc.contributor.author | Thompson, Craig B. | en_US |
dc.date.accessioned | 2010-06-01T21:50:32Z | |
dc.date.available | 2010-06-01T21:50:32Z | |
dc.date.issued | 1993-06 | en_US |
dc.identifier.citation | MITCHELL, BEVERLY S.; DAYTON, JENNIFER S.; TURKA, LAURENCE A.; THOMPSON, CRAIG B. (1993). "IMP Dehydrogenase Inhibitors as Immunomodulators." Annals of the New York Academy of Sciences 685(1 Immunomodulating Drugs ): 217-224. <http://hdl.handle.net/2027.42/74880> | en_US |
dc.identifier.issn | 0077-8923 | en_US |
dc.identifier.issn | 1749-6632 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/74880 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8103312&dopt=citation | en_US |
dc.format.extent | 422750 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | 1993 The New York Academy of Sciences | en_US |
dc.title | IMP Dehydrogenase Inhibitors as Immunomodulators | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Science (General) | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Howard Hughes Medical Institute University of Michigan Ann Arbor, Michigan 48109 | en_US |
dc.contributor.affiliationother | Departments of Pharmacology | en_US |
dc.contributor.affiliationother | Internal Medicine | en_US |
dc.contributor.affiliationother | University of North Carolina Chapel Hill, North Carolina 27599 Departments of Internal Medicine | en_US |
dc.contributor.affiliationother | Microbiology/Immunology | en_US |
dc.identifier.pmid | 8103312 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/74880/1/j.1749-6632.1993.tb35869.x.pdf | |
dc.identifier.doi | 10.1111/j.1749-6632.1993.tb35869.x | en_US |
dc.identifier.source | Annals of the New York Academy of Sciences | en_US |
dc.identifier.citedreference | Jackson, R. C. & G. Weber. 1975. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 256: 331 – 333. | en_US |
dc.identifier.citedreference | Koyama, H. & M. Tsuji. 1983. Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells. Biochem. Pharmacol. 32: 3547 – 3553. | en_US |
dc.identifier.citedreference | Sakaguchi, K., M. Tsujino, M. Hayashi, K. Kawai, J. Mizuno & K. Hayand. 1976. Mode of action of bredinin with guanylic acid on L5178Y mouse leukemia cells. J. Antibiotics (Tokyo) 29: 1320 – 1327. | en_US |
dc.identifier.citedreference | Ichikawa, Y., H. Ihara, S. Takahara, K. Takada, G. R. Shrestha, M. Ishibashi, M. Arima, S. Sagawa & T. Sonoda. 1984. The immunosuppressive mode of action of mizoribine. Transplantation 38: 262 – 267. | en_US |
dc.identifier.citedreference | Kusaba, R., O. Otubo, H. Sugimoto, I. Takahashi, Y. Yamada, J. Yamauchi, N. Akiyama & T. Inou. 1981. Immunosuppressive effect of bredinin in the management of patients with renal transplantation. In Proceedings of the European Dialysis Transplantation Association 18: 420 – 425. | en_US |
dc.identifier.citedreference | Amemiya, H., S. Suzuki, H. Watanabe, R. Hayashi & S. Niiya. 1989. Synergistically enhanced immunosuppressive effect by combined use of cyclosporine and mizoribine. Transplant. Proc. 21: 956 – 958. | en_US |
dc.identifier.citedreference | Amemiya, H., S. Suzuki, S. Niiya, H. Watanabe & T. Kotake. 1988. Synergistic effect of cyclosporine and mizoribine on survival of dog renal allografts. Transplantation 46: 768 – 771. | en_US |
dc.identifier.citedreference | Aso, K., H. Uchida, K. Sato, K. Yokota, T. Osakabe, Y. Nakayama, M. Ohkubo, K. Kumano, T. Endo, K. Koshiba, K. Watanabe & N. Kashiwagi. 1987. Immuno-suppression with low-dose cyclosporine combined with bredinin and prednisolone. Translant. Proc. 19: 1955 – 1958. | en_US |
dc.identifier.citedreference | Turka, L. A., J. Dayton, G. Sinclair, C. B. Thompson & B. S. Mitchell. 1991. Guanine ribonucleotide depletion inhibits T cell activation: mechanism of action of the immunosuppressive drug mizoribine. J. Clin. Invest. 87: 940 – 948. | en_US |
dc.identifier.citedreference | Sidi, Y. & B. S. Mitchell. 1984. 2'-Deoxyguanosine toxicity of B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulation. J. Clin. Invest. 74: 1640 – 1648. | en_US |
dc.identifier.citedreference | Dayton, J. S., L. A. Turka, C. B. Thompson & B. S. Mitchell. 1992. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide pools. Mol. Pharmacol. 41: 671 – 676. | en_US |
dc.identifier.citedreference | Cohen, M. B., J. Maybaum & W. Sadee. 1981. Guanine nucleotide depletion and toxicity in mouse T lymphoma (S-49) cells. J. Biol. Chem. 256: 8713 – 8717. | en_US |
dc.identifier.citedreference | Elion, G. B. & G. H. Hitchings. 1975. Azathioprine. Handb. Exp. Pharmacol. 38: 404 – 425. | en_US |
dc.identifier.citedreference | Wolberg, G. 1988. Antipurines and purine metabolism. Handb. Exp. Pharmacol. 85: 517 – 533. | en_US |
dc.identifier.citedreference | Marumo, F., M. Okubo, K. Yokota, H. Uchida, K. Kumano, T. Endo, K. Watanabe & N. Kashiwagi. 1988. A clinical study of renal transplant recipients receiving triple-drug therapy-cyclosporine A, mizoribine, and prednisolone. Transplant. Proc. 20: 406 – 409. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.